Treace Medical Concepts, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
Treace Medical Concepts, Inc. (TMCI) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum of 4.43% for the 12-month period ending 2024-12-31, per its 10-K filed 2026-02-27.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum · last filed 2026-02-27
- Treace Medical Concepts, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2021-06-30 was 1.07%.
- Treace Medical Concepts, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2021-03-31 was 0.09%, a 94.12% decline year-over-year.
- Treace Medical Concepts, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2020-03-31 was 1.53%.
- Treace Medical Concepts, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2024 was 4.43%, a 0.23% decline from fiscal 2023.
- Treace Medical Concepts, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2023 was 4.44%, a 2.30% increase from fiscal 2022.
- Treace Medical Concepts, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2022 was 4.34%, a 212.23% increase from fiscal 2021.
- Treace Medical Concepts, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2021 was 1.39%, a 9.15% decline from fiscal 2020.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 12 month |
|---|---|---|---|
| 2024-12-31 | 4.43% 10-K · filed 2026-02-27 | ||
| 2023-12-31 | 4.44% 10-K · filed 2026-02-27 | ||
| 2022-12-31 | 4.34% 10-K · filed 2025-02-27 | ||
| 2021-12-31 | 1.39% 10-K · filed 2024-02-27 | ||
| 2021-06-30 | 1.07% 10-Q · filed 2021-08-05 | 1.07% 10-Q · filed 2021-08-05 | |
| 2021-03-31 | 0.09% 10-Q · filed 2021-05-25 | ||
| 2020-12-31 | 1.53% 10-K · filed 2023-03-08 | ||
| 2020-06-30 | 1.53% 10-Q · filed 2021-08-05 | ||
| 2020-03-31 | 1.53% 10-Q · filed 2021-05-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| SHOULDER INNOVATIONS, INC. (SI) | United States | $0.355B | |
| Orchestra BioMed Holdings, Inc. (OBIO) | United States | $0.356B | -4.39 |